Published Date: 02 Mar 2023
The latest studies of long-acting ART show benefits even in people who are not immune. Meanwhile, early proof-of-concept results for twice-yearly injection are encouraging.
Read Full NewsCase shows importance of accurate preop diagnosis
Some panelists had reservations about the test's true benefit, however
— Trial of lirafugratinib showed responses in almost half of patients, with good durability
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation